Nicholas CR

Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53705, USA.

14 papers · 2 preprints · ORCID

ArticlePsilocybin

Electrophysiological effects of psilocybin co-administered with midazolam.

Sutherland MH, Nicholas CR, Lennertz RC +8

Europe PMC2026
ArticlePsychedelics

How do psychedelics impact people with a history of non-affective psychosis? A qualitative study.

Dourron HM, Copes H, Grossman DH +6

Europe PMC2025
PreprintPsilocybin

Electrophysiological effects of psilocybin co-administered with midazolam

Sutherland MH, Nicholas CR, Lennertz RC +8

Europe PMC2025
ArticlePsychedelics

Exploring psychedelic experiences among people who regularly use methamphetamine: Findings from an international survey.

Bahceci D, Siefried K, Steele M +9

Europe PMC2025
ArticlePsilocybin

A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.

Yaden DB, Graziosi M, Owen AM +39

Europe PMC2025
ArticleMDMA

The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSD.

O'Donnell KC, Okano L, Alpert M +6

Europe PMC2024
ArticleMDMA

Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.

Mitchell JM, Ot'alora G M, van der Kolk B +16

Europe PMC2024
ArticlePsilocybin

Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience.

Nicholas CR, Banks MI, Lennertz RC +9

Europe PMC2024
PreprintPsilocybin

Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience

Nicholas CR, Banks MI, Lennertz RL +9

Europe PMC2024
ArticlePsilocybin

Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.

O'Donnell KC, Anderson BT, Barrett FS +9

Europe PMC2024
ArticlePsilocybin

Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings.

Nicholas CR, Horton DM, Malicki J +3

Europe PMC2023
ArticleMDMA

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.

Mitchell JM, Ot'alora G M, van der Kolk B +16

Europe PMC2023
ArticlePsilocybin

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.

Raison CL, Sanacora G, Woolley J +31

Europe PMC2023
ArticlePsilocybin

Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder.

Brett J, Knock E, Korthuis PT +5

Europe PMC2023
ArticlePsilocybin

Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.

Goldberg SB, Shechet B, Nicholas CR +4

Europe PMC2020
ArticlePsilocybin

High dose psilocybin is associated with positive subjective effects in healthy volunteers.

Nicholas CR, Henriquez KM, Gassman MC +7

Europe PMC2018